Aspiriant Defensive Allocation Fund · NASDAQ:RMDFX
Aspiriant Defensive Allocation Fund — Aspiriant Risk-Managed Equity Allocation Fund — Fact Sheet (April 2026)
11 slides from Aspiriant Defensive Allocation Fund's fact sheet, April 2026
Slide 1: Aspiriant Risk-Managed Equity Allocation (RMEAX) Fact Sheets
Aspiriant Risk-Managed Equity Allocation (RMEAX) Fact Sheets aspiriant │ │ 34
Slide 2: RMEAX Summary: Investment Objective & Fund Description
RMEAX Summary Investment Objective & Fund Description Investment Objective The Aspiriant Risk-Managed Equity Allocation Fund (“RMEAX” or the “Fund”) seeks to achieve long-term capital appreciation while considering federal tax implications of investment decisions. Description The Fund in
Slide 3: RMEAX – Annualized & Cumulative Performance
RMEAX – Annualized & Cumulative Performance Generated reasonable returns and curtailed downside during market selloffs. Performance Performance QTD 1-YR 3-YR 5-YR 10-YR Incept. RMEAX has generated meaningful absolute returns RMEAX -3.38% 11.94% 13.18% 7.73% 8.27% 7.30% while exhibiting defen
Slide 4: RMEAX – Performance & Capture Ratio
RMEAX – Performance & Capture Ratio Greater consistency can help investors remain more comfortably invested. RMEAX Since Inception Performance Actual Return vs. Historical Performance Trend1 480 RMEAX has generated meaningful absolute returns while exhibiting defensiveness during selloffs.
Slide 5: RMEAX – Historical Allocations & Portfolio Positioning
RMEAX – Historical Allocations & Portfolio Positioning The Fund is well-diversified with access to skill-based managers. Historical Allocations Historical Allocations 100% The Fund currently employs three risk-managed strategies: minimum volatility, quality and long/short. 80% Combined, we
Slide 6: RMEAX – Regional and Style Exposures
RMEAX – Regional and Style Exposures Positioning relative to the Fund’s passive Benchmark (percentage difference). Region RMEAX vs. ACWI Underweight Overweight Region RMEAX Benchmark -4.67 North America 62.31 66.98 -2.19 Europe Developed 9.16 11.35 2.64 Asia Emerging 7.82 5.18 -3.33 Japan 1.
Slide 7: RMEAX vs Peer Group – Rolling Returns & Fund Expenses
RMEAX vs Peer Group – Rolling Returns & Fund Expenses Attractive absolute returns and low direct costs. 30.0% Relative to Peer Group Annualized Return 25.0% Throughout its history, the Fund had generated returns within the range of its peer group.1 20.0% Most of the peer group has underperfo
Slide 8: RMEAX vs Peer Group – Rolling Performance
RMEAX vs Peer Group – Rolling Performance Improving returns within its peer group range, while exhibiting lower risk. 30.0% 3-YR Rolling Return 3-Year Rolling Return 25.0% The Fund was largely in the bottom quartile of rolling 20.0% investment returns compared to its peer group1 over earlier 1
Slide 9: RMEAX – Annualized Return vs Risk
RMEAX – Annualized Return vs Risk Similar return with less risk than its peer group median. 5-YR 20.0% Return vs Risk – 5-Year Annualized RMEAX’s return has been comparable to its peer group1 15.0% median while it has exhibited significantly less risk. Return 10.0% 5.0% 0.0% 8.0% 10.0% 12.
Slide 10: RMEAX – Historical Monthly Performance
RMEAX – Historical Monthly Performance Attractive risk-adjusted return since inception. Monthly Investment Returns As of March 31, 2026 ACWI Min Vol Fund Annual ACWI Annual Annual Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Return Return Return 2026 2.15 0.48 -5.87 -3.38 -3.20 -0.32 2025
Slide 11: Additional Footnotes
Aspiriant Risk-Managed Equity Allocation (RMEAX) Additional Footnotes Please consider the Fund’s investment objectives, risks, charges and expenses carefully before investing. The prospectus that contains this and other information about the Fund is available by calling 1.877.997.9971 and sh
Aspiriant Risk-Managed Equity Allocation Fund — Fact Sheet (April 2026) on 6ix